GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.

1

Semaglutide was linked to a 42% lower risk of worsening mental illness in patients with depression or anxiety on noninsulin antidiabetic therapy.
2

The study analyzed 95,490 patients from Sweden between 2009 and 2022, focusing on psychiatric outcomes related to GLP-1 receptor agonists.
3

Liraglutide showed a modest reduction in mental illness risk, while exenatide and dulaglutide did not demonstrate any significant difference.
4

Secondary analyses indicated semaglutide reduced risks of worsening depression, anxiety, and substance use disorder.
5

The study's design compared periods of GLP-1 RA use and nonuse within the same patient, although causality could not be established.

1